Details

Autor(en) / Beteiligte

• Vakrakou, Aigli G.
• Tzanetakos, Dimitrios
• Evangelopoulos, Maria-Eleptheria
• Fragoulis, George E.
• Kazakou, Paraskevi
• Lekka, Eleni
• Kafasi, Nikolitsa
• Tzartos, John S.
• Andreadou, Elissavet
• Koutsis, Georgios
• Gialafos, Elias
• Dimitrakopoulos, Antonios
• Zampeli, Evanthia
• Rontogianni, Dimitra
• Theocharis, Stamatios
• Zapanti, Evangelia
• Stathopoulos, Panos-Alexis
• Anagnostouli, Maria
• Stefanis, Leonidas
• Kilidireas, Constantinos

Titel

IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients

Ist Teil von

• Journal of neuroimmunology, 2021-12, Vol.361, p.577759-577759, Article 577759

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• We aimed to determine whether Alemtuzumab-induced immune reconstitution affects immunoglobulin and complement levels in the serum of Relapsing-Remitting Multiple Sclerosis (RRMS) patients. IgG4-levels were increased 24-months after treatment initiation compared to baseline levels in twenty-nine patients. Alemtuzumab-treated patients with the highest IgG4-levels were more prone to thyroid-related autoimmune manifestations and specific autoimmune adverse events such as Crohn's disease, Graves' disease, and hemolytic anemia. Compared to baseline, total IgG-levels showed a trend towards reduced levels following two-courses of Alemtuzumab, but no significant change of C3 and/or C4-levels was observed. In conclusion, monitoring of IgG4-levels can serve as a marker for secondary autoimmunity risk in multiple sclerosis patients treated with Alemtuzumab. [Display omitted] •Distinct modulation pattern of serum IgG4 compared to IgG in Alemtuzumab treated Multiple Sclerosis patients.•IgG4/IgG ration displayed significant increase after 12-months from treatment initiation.•Patients with high IgG4-levels were more prone to autoimmune manifestations.•The highest IgG4 levels were found among patients developing Grave's disease.•Monitoring IgG4-levels could represent a surrogate marker of late-onset autoimmunity.